Table 4 LncRNA and drug resistance in prostate cancer.
From: Role of noncoding RNA in drug resistance of prostate cancer
LncRNAs | Expression | Genes and pathways | Drug | Reference |
|---|---|---|---|---|
HOXD-AS1 | Up | WDR5/H3K4me3 | Bicalutamide | |
LncRNA-HOTAIR | Up | AR | Androgen | |
Lnc-LBCS | Down | hnRNPK/AR | Androgen | |
LncRNA-BCAR4 | Up | GLI2 | Androgen | |
LncRNA-SNHG6 | Up | miR-186/CD51 | Androgen | |
Linc00675 | Up | MDM2/GATA2/AR | Androgen | |
Linc00518 | Up | miR-216b-5p/GATA | Paclitaxel | |
LncRNA-CCAT1 | Up | miR-24–3p/FSCN1 | Paclitaxel | |
LncRNA-NEAT1 | Up | miR-34a-5p and miR-204–5p/ASCL4 | Docetaxel | |
LncRNA-MALAT1 | Up | miR-145–5p/AKAP12 | Docetaxel | |
LncRNA-DANCR | Up | miR-34a-5p/JAG1 or miR-135a | Docetaxel | |
LncRNA-CASC2 | Down | miR-183/SPRY2 | Docetaxel | |
LncRNA-HORAS5 | Up | BCL2A1 | Cabazitaxel | |
LncRNA-HOTTIP | Up | Wnt/β-catenin | Cisplatin | |
LOXL1-AS1 | Down | miR-let-7a-5p/EGFR | Doxorubicin |
